Joshua Jennings
Stock Analyst at TD Cowen
(2.62)
# 2,248
Out of 5,051 analysts
72
Total ratings
46.15%
Success rate
4.16%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Buy | $85 → $50 | $31.86 | +56.94% | 4 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $58.80 | +42.86% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.48 | +137.29% | 3 | Aug 12, 2025 | |
| SENS Senseonics Holdings | Initiates: Buy | $25 | $6.73 | +271.47% | 1 | Jul 15, 2025 | |
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.31 | +248.03% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $315.30 | +2.76% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $98.72 | +11.43% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $11.70 | +207.69% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $127.00 | -5.51% | 9 | Nov 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $1.70 | +2,841.18% | 1 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $88.85 | +33.94% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $36.22 | +65.65% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $77.53 | +3.19% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $12.46 | +261.16% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $82.94 | -15.60% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $185.82 | -0.44% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $17.90 | +123.46% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $356.18 | +12.30% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $61.69 | -2.74% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $14.70 | +131.37% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $5.88 | +206.12% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $18.30 | +36.61% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $124.14 | +4.72% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.80 | +78.57% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $89.84 | +30.23% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $4.54 | +9,808.40% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $19.84 | -39.50% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $176.09 | +56.17% | 1 | Feb 7, 2020 |
PROCEPT BioRobotics
Nov 5, 2025
Maintains: Buy
Price Target: $85 → $50
Current: $31.86
Upside: +56.94%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $58.80
Upside: +42.86%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.48
Upside: +137.29%
Senseonics Holdings
Jul 15, 2025
Initiates: Buy
Price Target: $25
Current: $6.73
Upside: +271.47%
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.31
Upside: +248.03%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $315.30
Upside: +2.76%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $98.72
Upside: +11.43%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $11.70
Upside: +207.69%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $127.00
Upside: -5.51%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $1.70
Upside: +2,841.18%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $88.85
Upside: +33.94%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $36.22
Upside: +65.65%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $77.53
Upside: +3.19%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $12.46
Upside: +261.16%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $82.94
Upside: -15.60%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $185.82
Upside: -0.44%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $17.90
Upside: +123.46%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $356.18
Upside: +12.30%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $61.69
Upside: -2.74%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $14.70
Upside: +131.37%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $5.88
Upside: +206.12%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $18.30
Upside: +36.61%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $124.14
Upside: +4.72%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.80
Upside: +78.57%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $89.84
Upside: +30.23%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $4.54
Upside: +9,808.40%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $19.84
Upside: -39.50%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $176.09
Upside: +56.17%